Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab | Zendy

CherylC Ho | Zendy; A. Ye | Zendy; JohnH Hay | Zendy; JanessaJ Laskin | Zendy; JonnS Wu | Zendy

Open Access

Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab

Author(s) -

CherylC Ho,

A. Ye,

JohnH Hay,

JanessaJ Laskin,

JonnS Wu

Publication year - 2013

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.126455

Subject(s) - medicine , cetuximab , mucositis , head and neck squamous cell carcinoma , rash , oncology , nausea , radiation therapy , toxicity , univariate analysis , head and neck cancer , multivariate analysis , cancer , colorectal cancer

The standard of care for locally advanced head and neck squamous cell carcinoma (HNSCC) is radiation therapy (RT) with concurrent cisplatin (CIS). Patients with renal or cardiac dysfunction, hearing loss or poor performance status (PS) may receive RT and cetuximab (CET) at our institution. This study compares treatment toxicities and outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research